糖尿病前期亚组、2型糖尿病风险及预防干预的差异效应
研究基于糖尿病预防计划3145名参与者的22项临床生物标志物,用K-means聚类得出两个糖尿病前期亚组:亚组1(严重胰岛素抵抗伴严重肥胖,占31%)和亚组2(中度胰岛素抵抗伴超重或肥胖,占69%)。亚组1糖尿病风险比亚组2高58%(HR 1.58,95%CI 1.31–1.91);生活方式干预使两组糖尿病风险减半,二甲双胍对亚组1获益更大(交互P<.05)。临床变量模型对糖尿病风险的判别优于聚类策略。
要点
- 糖尿病前期可分为严重胰岛素抵抗伴严重肥胖(31%)和中度胰岛素抵抗伴超重或肥胖(69%)两个亚组。
- 亚组1糖尿病风险比亚组2高58%(HR 1.58,95%CI 1.31–1.91)。
- 二甲双胍对亚组1的预防获益大于亚组2(交互P<.05),生活方式干预使两组风险减半。
核心结论
- 病理生理上不同的糖尿病前期亚组在糖尿病风险和二甲双胍预防获益上存在差异;作者认为这些结果支持糖尿病易感性存在不同机制,但使用临床预测模型指导治疗决策可能提供足够的风险分层。
研究设计与样本
- 研究使用糖尿病预防计划试验中3145名参与者的基线数据,以22项临床生物标志物(经性别标准化)进行K-means聚类推导糖尿病前期亚组。
- 采用Cox比例风险回归估计各亚组糖尿病风险比及不同干预(强化生活方式、二甲双胍或安慰剂)的差异效应,并将聚类策略与临床变量模型进行比较。
主要发现
- 共识别出2个糖尿病前期亚组:亚组1以严重胰岛素抵抗伴严重肥胖为特征,占样本31%;亚组2以中度胰岛素抵抗伴超重或肥胖为特征,占69%。
- 亚组1糖尿病风险比亚组2高58%(HR 1.58,95%CI 1.31–1.91)。
- 与安慰剂相比,随机分配至生活方式干预使两个亚组的糖尿病风险均减半。
- 二甲双胍对亚组1的获益大于亚组2(交互P<.05)。
- 临床变量模型对糖尿病风险的判别优于聚类策略。
临床怎么用
- 作者认为,这些结果支持糖尿病易感性存在不同机制;然而,使用临床预测模型指导治疗决策可能提供足够的风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior studies have subclassified type 2 diabetes using statistical clustering approaches with clinical data, but few have subclassified prediabetes and assessed the effects of preventive interventions. Our objective was to derive prediabetes subgroups based on clinical biomarkers and assess risk for incident diabetes and differential preventive intervention effects within the derived subgroups, with comparison to more simple modeling approaches. METHODS: Baseline data for 3145 participants in the Diabetes Prevention Program trial were used to derive prediabetes subgroups using K-means clustering with data for 22 clinical biomarkers (sex-standardized). Cox proportional hazards regression was used to estimate hazard ratios (HRs) for diabetes and differential intervention effects (intensive lifestyle, metformin, or placebo) by prediabetes subgroups and to compare the clustering strategy to a model with clinical variables. RESULTS: We identified 2 prediabetes subgroups characterized by severe insulin resistance with severe obesity (subgroup 1, 31% of sample) and moderate insulin resistance with overweight or obesity (subgroup 2, 69%). Subgroup 1 had a 58% higher risk for diabetes (HR: 1.58, 95% confidence interval: 1.31, 1.91) compared to subgroup 2. Randomization to lifestyle (compared to placebo) halved diabetes risk for both subgroups, while metformin provided greater benefit to subgroup 1 vs subgroup 2 (P for interaction <.05). A clinical variable model discriminated diabetes risk better than the clustering strategy. CONCLUSION: Pathophysiologically distinct prediabetes subgroups differ in risk for diabetes and preventive benefit from metformin. These results support distinct mechanisms of diabetes susceptibility; however, the use of clinical prediction models to guide treatment decisions may provide adequate risk profiling.
引用
- Stafford JM, Casanova R, Jaeger BC, et al. Prediabetes Subgroups, Type 2 Diabetes Risk, and Differential Effects of Preventive Interventions. J Clin Endocrinol Metab. 2025. PMID: 40497454. doi:10.1210/clinem/dgaf350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。